Mobile Site ›

Free Light Chains & Monoclonal Gammopathies

Impact on Diagnostic Panels



Introduction

Slide 1

August 2008

Welcome to Mayo Medical Laboratories' Hot Topics. These presentations provide short discussion of current topics and may be helpful to you in your practice.

With the introduction of Mayo's expanded serum monoclonal protein panel, which includes quantitation of the kappa and lambda free light chains, urine monoclonal protein studies are no longer required as part of the initial diagnostic screen for monoclonal gammopathies.

Jerry Katzmann, PhD, from the Division of Clinical Biochemistry and Immunology at Mayo Clinic, discusses Mayo's approach to the diagnosis of monoclonal gammopathies and the use of serum free light chain assays.

Introduction

 

Jump to section:


Key